.jpg)
1 hour ago
3
Article content
bioLytical’s iStatis test delivers results in 15 minutes in clinical and community settings
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
A Critical Step in Hepatitis B Diagnosis and Prevention in Canada
Article content
Article content
- bioLytical’s iStatis Hepatitis Surface Antigen Test (iStatis HBsAg Test) has received Health Canada authorization for use as a Point-of-Care Test (POCT)
- The first Health Canada-authorized point-of-care test for hepatitis B surface antigen and the first of its kind in North America
- Enables detection of the hepatitis B surface antigen with high sensitivity and specificity
- Portable and accurate; ideal for clinics, outreach settings, and community-based care
- Expanded access supports Canada’s public health goals and the WHO target to eliminate viral hepatitis as a public health threat by 2030
Article content
Article content
Canada Approves First Rapid Point-of-Care Test for Hepatitis B
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
RICHMOND, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) — Canada has authorized its first rapid point-of-care test for hepatitis B, marking a North American first and a significant step toward improving access to screening and early diagnosis.
Article content
Developed by bioLytical Laboratories Inc., the iStatis Hepatitis B Surface Antigen (HBsAg) Test delivers results in 15 minutes and is designed for use in clinics, mobile units, outreach programs, and community-based settings where traditional lab testing may be less accessible.
Article content
The approval comes as hepatitis B remains a major but underdiagnosed public health issue in Canada. More than 260,000 Canadians are living with chronic hepatitis B, yet nearly half are unaware of their infection status, according to public health estimates.
Article content
Addressing Gaps in Hepatitis B Diagnosis
Article content
Limited access to timely testing continues to be a barrier, particularly in remote, underserved, and high-risk communities. Rapid point-of-care testing allows healthcare providers to screen and deliver results during a single visit, helping connect patients to care sooner.
Article content
Article content
“Too many people with hepatitis B remain undiagnosed because testing isn’t always accessible,” said Robert Mackie, CEO of bioLytical Laboratories. “This authorization allows screening to move closer to the patient, whether that’s in a clinic, a mobile unit, or a community outreach setting.”
Article content
The iStatis HBsAg Test detects the hepatitis B surface antigen, a marker of active infection, enabling healthcare providers to make informed decisions quickly and initiate follow-up care where needed.
Article content
A Tool for Frontline and Community-Based Care
Article content
Designed for decentralized use, the test requires minimal training and no additional instrumentation. Its portability and ease of use make it suitable for a wide range of care environments, including harm reduction services and community health programs.
Article content
“Rapid, reliable screening at the point of care can make a meaningful difference in how quickly patients are diagnosed and linked to treatment,” said Dan Wang, Director of Scientific Affairs at bioLytical. “This test brings accurate hepatitis B screening directly to frontline healthcare providers.”
English (US)